Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00033072

Enrollment

Registered

2002-04-08

Start date

2001-09-30

Completion date

2002-10-31

Last updated

2017-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amphetamine-Related Disorders

Brief summary

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Detailed description

To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.

Interventions

DRUGSelegiline

Study design

Allocation

RANDOMIZED

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals * Be able to verbalize understanding of consent form; provide written informed consent

Exclusion criteria

* Please contact site for more information

Design outcomes

Primary

Measure	Time frame
safety of selegiline	—
pharmacokinetic assessment	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026